Literature DB >> 12621594

Prevalence and relationship to delusions and hallucinations of anxiety disorders in schizophrenia.

Philip Tibbo1, Jennifer Swainson, Pierre Chue, Jean-Michel LeMelledo.   

Abstract

We investigated the prevalence of anxiety disorders in a sample of individuals with chronic schizophrenia, controlling for anxiety symptoms that may be related to delusions and hallucinations, and the possible differences in clinical variables between the groups. Individuals with a diagnosis of schizophrenia and able to give informed consent were recruited from the community. The Mini International Neuropsychiatric Interview (MINI) was administered to both confirm the DSM-IV diagnosis of schizophrenia and screen for comorbid anxiety disorders. If a comorbid anxiety disorder was found, its relation to the individual's delusions and hallucinations was examined. Clinical rating scales for schizophrenia were administered as well as rating scales for specific anxiety disorders where appropriate. Overall, anxiety disorders ranged from 0% [ for Post Traumatic Stress Disorder (PTSD)] to 26.7% [ for generalized anxiety disorder (GAD) and agoraphobia without panic] with lower rates when controlled for anxiety symptoms related to delusions and hallucinations. In investigating clinical variables, the cohort was initially divided into schizophrenics with no anxiety disorders and those with an anxiety disorder; with further analyses including schizophrenics with anxiety disorders related to delusions and hallucinations and those with anxiety disorders not related to delusions and hallucinations. The most consistent difference between all the groups was on the PANSS-G subscale. No significant differences were found on the remaining clinical variables. Comorbid anxiety disorders in schizophrenia can be related to the individual's delusions and hallucinations, though anxiety disorders can occur exclusive of these positive symptoms. Clinicians must be aware that this comorbidity exists in order to optimize an individual's treatment. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12621594     DOI: 10.1002/da.10083

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  15 in total

1.  An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses.

Authors:  A Carlo Altamura; Marta Serati; Alessandra Albano; Riccardo A Paoli; Ira D Glick; Bernardo Dell'Osso
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-02-18       Impact factor: 5.270

Review 2.  Anxiety in Patients with Schizophrenia: Epidemiology and Management.

Authors:  Henk Temmingh; Dan J Stein
Journal:  CNS Drugs       Date:  2015       Impact factor: 5.749

3.  The clinical-basic interface in defining pathogenesis in disorders of neurodevelopmental origin.

Authors:  Barbara L Thompson; Pat Levitt
Journal:  Neuron       Date:  2010-09-09       Impact factor: 17.173

4.  Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats.

Authors:  Maria Sabrina Spano; Liana Fattore; Francesca Cadeddu; Walter Fratta; Paola Fadda
Journal:  Psychopharmacology (Berl)       Date:  2012-08-19       Impact factor: 4.530

Review 5.  How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association.

Authors:  Amélie M Achim; Michel Maziade; Eric Raymond; David Olivier; Chantal Mérette; Marc-André Roy
Journal:  Schizophr Bull       Date:  2009-12-03       Impact factor: 9.306

6.  Paranoid Thoughts in Adolescents with Social Anxiety Disorder.

Authors:  S Pisano; G Catone; A Pascotto; R Iuliano; C Tiano; A Milone; G Masi; A Gritti
Journal:  Child Psychiatry Hum Dev       Date:  2016-10

Review 7.  Psychiatric comorbidities and schizophrenia.

Authors:  Peter F Buckley; Brian J Miller; Douglas S Lehrer; David J Castle
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

8.  Psychiatric comorbidity among adults with schizophrenia: a latent class analysis.

Authors:  Jack Tsai; Robert A Rosenheck
Journal:  Psychiatry Res       Date:  2013-05-30       Impact factor: 3.222

Review 9.  Schizophrenia: a systemic disorder.

Authors:  Brian Kirkpatrick; Brian Miller; Clemente García-Rizo; Emilio Fernandez-Egea
Journal:  Clin Schizophr Relat Psychoses       Date:  2014-07

10.  Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol.

Authors:  A A Boucher; J C Arnold; L Duffy; P R Schofield; J Micheau; T Karl
Journal:  Psychopharmacology (Berl)       Date:  2007-02-28       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.